WWTR1 and cancer: Blocking TAZ activity within tumour cells might thus have a dual beneficial role, by both suppressing intrinsic malignant features of the cancer cells and reversing the immune suppressive TME, thereby potentially also rendering the tumours more vulnerable to immunotherapy.